GlassScriptPhysician profile
Evangeline Friedbaum
NPI 1073225348
$261.98
in general payments reported to CMS, 2019-2025
11 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $140 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $261.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $48.79 | 2024-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $37.71 | 2024-2025 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.68 | 2024-2025 | Caplyta |
| Amphastar Pharmaceuticals, INC. | $22.52 | 2024 | |
| Abbvie INC. | $21.40 | 2024 | |
| Organon LLC | $19.08 | 2024 | |
| Exeltis, USA INC. | $16.74 | 2025 | Slynd |
| Takeda Pharmaceuticals U.S.A., INC. | $15.52 | 2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $15.16 | 2024 | Eliquis |
| Vanda Pharmaceuticals INC. | $14.42 | 2025 | Fanapt |
| Astellas Pharma US INC | $13.96 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evangeline Friedbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.